Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/03/22
Cidara Therapeutics Receives $11.1 Million Milestone Payment from MundipharmaGlobeNewsWire • 10/04/22
Cidara Therapeutics Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive CandidiasisGlobeNewsWire • 09/20/22
Cidara Therapeutics Announces Initiation of Phase 2a Human Viral Challenge Trial to Evaluate CD388 for Universal Prevention of InfluenzaGlobeNewsWire • 09/13/22
Cidara Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 09/06/22
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial ResultsGlobeNewsWire • 08/09/22
Melinta Therapeutics and Cidara Therapeutics Announce Licensing Agreement to Commercialize Rezafungin in the U.S.Business Wire • 07/27/22
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.GlobeNewsWire • 07/27/22
Tentarix Biotherapeutics Announces the Strengthening of its Leadership and Advisory TeamsBusiness Wire • 05/20/22
Cidara Therapeutics (CDTX) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/11/22
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2022 Financial ResultsGlobeNewsWire • 05/11/22
Mundipharma and Cidara Therapeutics Announce First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety ProfileBusiness Wire • 04/25/22
Cidara Therapeutics and Mundipharma to Present Results from Global Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and/or Invasive Candidiasis at ECCMID 2022GlobeNewsWire • 04/14/22
Cidara Therapeutics Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic InfluenzaGlobeNewsWire • 03/31/22
Cidara Therapeutics (CDTX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/08/22
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 03/07/22
Rezafungin Awarded Promising Innovation Medicine (PIM) Designation by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the Treatment of Invasive CandidiasisBusiness Wire • 03/03/22
Will Cidara Therapeutics (CDTX) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/17/22
FDA Clears Cidara Therapeutics' Phase 1 Trial For Immunotherapeutic Antiviral For InfluenzaBenzinga • 02/14/22
Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of InfluenzaGlobeNewsWire • 02/14/22
Cidara Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 01/06/22
Cidara Therapeutics Stock Slides Despite Acing Rezafungin Trial In Fungal InfectionBenzinga • 12/14/21